James Chu, MD
Endocrinology, Diabetes & Metabolism · Monterey, CANPI 1710969266
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $568,785 of the $638,969 with a category attached, or 89.0%. Lilly USA, LLC accounts for 77.8% of it on its own, with 36 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,430 payments — averaging $446.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$497K
- Boehringer Ingelheim$82K
- Sanofi-aventis U.S. LLC$33K
- AstraZeneca$21K
- Abbott$828
- Amgen$615
- plus $4K from 31 others
Across 396 payments — averaging $1233.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$271K
- Novo Nordisk AS$218K
What the payments were for
- Consulting fees$4,0001%
- Speaking & faculty fees$568,78589%
- Travel & lodging$43,4917%
- Food & beverage$22,6644%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 913 | $497,050 |
| Boehringer Ingelheim | 143 | $82,358 |
| Sanofi-aventis U.S. LLC | 72 | $32,788 |
| AstraZeneca(2 entities) | 68 | $21,441 |
| Abbott | 43 | $828 |
| Amgen(2 entities) | 28 | $615 |
| Bayer | 11 | $410 |
| Dexcom, Inc. | 13 | $375 |
| Xeris Pharmaceuticals, Inc. | 18 | $364 |
| Mannkind Corporation | 17 | $329 |
| Radius Health, Inc. | 13 | $319 |
| AbbVie | 16 | $262 |
| Novo Nordisk | 6 | $234 |
| Corcept Therapeutics | 6 | $179 |
| Johnson & Johnson | 10 | $157 |
| Merck | 7 | $123 |
| Kyowa Kirin, Inc. | 5 | $115 |
| Medtronic(2 entities) | 4 | $107 |
| Ascendis Pharma Endocrinology Inc | 4 | $103 |
| Madrigal Pharmaceuticals | 3 | $100 |
| Eli Lilly | 2 | $75 |
| BETA Bionics, Inc. | 3 | $72 |
| Ascensia Diabetes Care US Inc. | 3 | $69 |
| Cequr Corporation | 1 | $63 |
| Shire North American Group Inc | 3 | $61 |
| Insulet Corporation | 3 | $59 |
| Tandem Diabetes Care, Inc. | 2 | $58 |
| Eli Lilly Export S.A. Puerto Rico Branch | 3 | $43 |
| Boston Scientific | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Soleno Therapeutics, Inc. | 1 | $27 |
| Sequel Med Tech, LLC | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Tolmar, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$231,543
- MOUNJARO$160,621
- JARDIANCE$142,700
- SOLIQUA 100/33$23,377
- FARXIGA$20,270
- TOUJEO$8,363
- Kerendia$234
- FREESTYLE LIBRE 3$113
How this compares
$638,969 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 326 | $356,548 |
| TrulicityDulaglutide | 192 | $344,021 |
| JardianceEmpagliflozin | 105 | $131,390 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 80 | $105,470 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 70 | $89,319 |
| OzempicSemaglutide | 60 | $65,641 |
| TradjentaLinagliptin | 50 | $63,766 |
| JanuviaSitagliptin Phosphate | 41 | $55,447 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $40,197 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $36,411 |
| TymlosAbaloparatide | 13 | $35,884 |
| RybelsusSemaglutide | 18 | $27,852 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $26,752 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $23,283 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $17,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $497,050 | $700,569518 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $82,358 | $300,627235 claims |
| Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30 | $234 | $97,97489 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $32,788 | $89,31970 claims |
| MerckJanuvia, Janumet Xr | $123 | $82,19962 claims |
| Radius Health, Inc.Tymlos | $319 | $35,88413 claims |
| AbbVieSynthroid | $262 | $17,237221 claims |
| AstraZenecaFarxiga | $21,441 | $15,05711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Monterey
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
- Athena Philis-Tsimikasla Jolla$574K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.